Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention with Drug-Eluting Stent Implantation: A Review of the Current Guidelines and Literature

2011 ◽  
Vol 39 (4) ◽  
pp. 32-40 ◽  
Author(s):  
Gilles Lemesle ◽  
Francesco Paparoni ◽  
Cedric Delhaye ◽  
Laurent Bonello ◽  
Jean-Marc Lablanche
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Antiplatelet Therapy ◽  
Stent Implantation ◽  
Dual Antiplatelet Therapy ◽  
Coronary Intervention ◽  
Drug Eluting Stent ◽  
Percutaneous Coronary ◽  
Drug Eluting ◽  
Current Guidelines

Dual Antiplatelet Therapy After Drug-eluting Stent Implantation

2016 ◽  
Vol 11 (1) ◽  
pp. 51
Author(s):  
Giulia Magnani ◽  
◽  
◽  
Marco Valgimigli
Keyword(s):  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Bleeding Risk ◽  
Coronary Intervention ◽  
Drug Eluting Stent ◽  
P2y12 Inhibitor ◽  
Percutaneous Coronary ◽  
Drug Eluting ◽  
Meta Analyses ◽  
Current Guidelines

The current guidelines for percutaneous coronary intervention use recommend dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor after drug eluting stent (DES) implantation. The optimal duration of DAPT is however area of debate. Recent clinical trials and meta-analyses suggest that the choice of DAPT duration should be tailored individually, based on the balance between ischemic and bleeding risk carried by the patient.

Sign in / Sign up

Export Citation Format

Share Document